CAR T

Oricell’s OriC-902 shows robust results in HCC

Thu, 28 May 2026 09:00:00 -0400

At the ongoing European Association for the Study of the Liver 2026 annual meeting in Barcelona, researchers from Oricell Therapeutics Co. Ltd. presented data on a CAR T-cell approach targeting glypican 3 (GPC3) – OriC-902 – for the treatment of GPC3+ hepatocellular carcinoma (HCC).

Dual-targeting, rapamycin-enhanced CAR T for multiple myeloma

Fri, 22 May 2026 09:00:00 -0400

Umoja Biopharma Inc. performed preclinical studies to evaluate the antitumor activity of UB-VV500, an off-the-shell lentiviral vector CAR T-cell product. It is based on its Vivovec technology and designed to engineer fully human anti-B-cell maturation antigen (BCMA)/G protein-coupled receptor class C group 5 member D (GPRC5D) dual-targeting chimeric antigen receptor (CAR) T cells, for the potential treatment of multiple myeloma (MM).

FDA clears Qihan Biotech’s CAR T therapy QT-019C for clinic

Thu, 21 May 2026 09:00:00 -0400

Hangzhou Qihan Biotech Co. Ltd. has obtained IND clearance from the FDA for QT-019C, a universal allogeneic CAR T-cell therapy for autoimmune diseases. QT-019C cell injection is an off-the-shelf allogeneic CAR T-cell therapy engineered from healthy donor leukapheresis products to stably express two distinct CARs targeting CD19 and BCMA.

MD Anderson gains IND nod for CD94-targeted CAR T therapy

Mon, 18 May 2026 09:00:00 -0400

The University of Texas MD Anderson Cancer Center has received IND clearance from the FDA to initiate a phase I trial of a novel CAR T-cell therapy, JV-394, for patients with relapsed or refractory CD94-positive T/natural killer (NK) cell lymphomas.

Financing at Create Medicines to advance in vivo CAR therapies

Fri, 15 May 2026 09:00:00 -0400

Create Medicines Inc. has closed a $122 million series B funding round to support progression of its pipeline of in vivo CAR therapies across autoimmune disease and oncology. The company’s proprietary mRNA-LNP platform directly engineers T cells, NK cells and myeloid cells inside the body to enable scalable, repeat-dose, off-the-shelf immunotherapies.

ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

Wed, 13 May 2026 09:00:00 -0400

Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine, this RNA fragment without free ends surpasses their performance in both efficacy and durability, bringing it to the attention of several pioneering companies. The latest advances in circRNA presented at the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) clearly surpass the performance achieved with linear mRNA.

Seed financing at Parcelbio to advance mRNA medicines

Fri, 08 May 2026 09:00:00 -0400

Parcelbio has raised $13 million in seed financing to continue its development of a new class of potent and durable mRNA medicines. The financing will support development of Parcelbio’s proprietary APEXm (Amplified and Prolonged EXpression mRNA) platform and advance its pipeline, including its lead in vivo CAR T program for autoimmune disease.

PD-L1 CAR T cells simultaneously target tumor cells and the immunosuppressive TME in CCA

Mon, 20 Apr 2026 09:00:00 -0400

Although antibodies to PD-L1 are used in the clinic, their benefit is limited by immune exclusion within the local microenvironment. Objective response rates with anti-PD-L1 monotherapy are low due to the heterogeneity of PD-L1 expression, low tumor mutational burden and the highly immunosuppressive tumor microenvironment (TME) of cholangiocarcinoma (CCA).

CGT-19 as an approach to expand CAR T-cell therapy accessibility

Mon, 30 Mar 2026 09:00:00 -0400

The use of CAR T-cell therapy has transformed outcomes for relapsed or refractory B-cell malignancies, but access to it remains extremely limited in some countries. Cartogene Therapeutics Pvt Ltd. aimed to address this need by in-licensing CGT-19, a CD19 CAR T construct from Vector Biomed Inc.

CAR T targeting CD44E splicing variant shows potential for HCC treatment

Fri, 27 Mar 2026 09:00:00 -0400

Previously, Chinese researchers used long-read RNA sequencing to identify a unique alternative splicing variant of CD44 transmembrane protein, named CD44E, which is highly expressed in hepatocellular carcinoma (HCC) tumors compared to adjacent nontumoral liver tissues. In a new study, the team analyzed the Genotype-Tissue Expression (GTEx) database and confirmed that CD44E expression is limited in essential normal organs, while CD44S standard isoform is broadly expressed on most cell types.

Approach to enhance CAR T efficacy in infectious diseases and cancer

Thu, 26 Mar 2026 09:00:00 -0400

CAR T-cell therapy can be applied to treat some chronic infectious diseases, particularly to provide a functional cure for HIV-1 in people living with HIV. However, the effectiveness of CAR T cells for persistent suppression of HIV still faces many constraints, including the high mutation rate of reverse transcriptase, which enables the emergence of immune escape viral variants.

Overt Bio advances OVT-101 toward clinic

Tue, 24 Mar 2026 09:00:00 -0400

Overt Bio Inc. is advancing lead asset OVT-101 toward the clinic. The allogeneic, potential first-in-class, off-the-shelf γδ CAR T therapy targets claudin-6, which is present in the majority of ovarian cancers and several other solid tumors.

Nanobody CAR construct targeting CLL-1 shows preclinical activity against AML

Wed, 18 Mar 2026 09:00:00 -0400

Researchers from the Sino-American Cancer Foundation and Taipei Medical University have developed a novel nanobody-based CAR T-cell platform directed against C-type lectin-like molecule-1 (CLL-1) for the possible treatment of acute myeloid leukemia (AML).

DR5 as promising CAR T-cell target allowing inhibition of tumor cells and MDSCs

Wed, 11 Mar 2026 09:00:00 -0400

University of Pennsylvania researchers investigated death receptor 5 (DR5 or CD262) as a chimeric antigen receptor (CAR) target for solid tumors.

HITting solid tumors with a closer look and a stronger CAR T cell

Mon, 02 Mar 2026 08:00:00 -0500

CAR T cells have been groundbreaking for the treatment of B-cell cancers. But 8 years after Kymriah (tisagenlecleucel, Novartis AG) became the first CAR T-cell therapy to be approved, there are no CAR Ts approved for solid tumors.

Nanobody-based CLL-1-targeted CAR T cells enhance AML killing with reduced off-target effects

Thu, 26 Feb 2026 08:00:00 -0500

To overcome the challenges of current CAR T-cell strategies and enhance their efficacy and specificity for acute myeloid leukemia, researchers at the Sino-American Cancer Foundation and collaborating institutions have developed a nanobody-based CAR T-cell platform directed against C-type lectin-like molecule-1 (CLL-1).

TRX-319 silences autoreactive B and T cells in multiple sclerosis

Wed, 11 Feb 2026 08:00:00 -0500

Researchers from Tr1x Inc. presented the development of TRX-319, a novel allogeneic regulatory T-cell therapy designed for the treatment of autoimmune disorders.

Tempest Therapeutics outlines plans for acquired CAR T assets

Wed, 11 Feb 2026 08:00:00 -0500

Tempest Therapeutics Inc. has outlined plans to advance its newly acquired CAR T assets. While prioritizing development of its clinical-stage dual-targeting CD19/BCMA CAR-T program, TPST-2003 (ERI-2003), the company will also expand its portfolio into next-generation modalities.

In vivo CAR T cells reduce liver fibrosis

Mon, 02 Feb 2026 08:00:00 -0500

Liver fibrosis in the course of metabolic dysfunction-associated steatohepatitis could be significantly reduced using CAR T-cells generated in vivo. Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental cell therapy that eliminates only one type of liver cell, the stellate cells that express fibroblast activation protein alpha. This strategy not only reduced fibrosis but also reversed liver damage.

Selective CAR T targeting mutant CALR shows preclinical activity against MPNs

Wed, 28 Jan 2026 08:00:00 -0500

Despite the successful application of adoptive T-cell transfer with chimeric antigen receptor (CAR)-engineered T cells for the treatment of various hematologic malignancies, several other hematologic disorders, such as BCR::ABL1-negative myeloproliferative neoplasms (MPNs), still lack effective treatment options.

In vivo CAR T cells reduce liver fibrosis

Tue, 27 Jan 2026 08:00:00 -0500

Liver fibrosis in the course of metabolic dysfunction-associated steatohepatitis (MASH) could be significantly reduced using CAR T-cells generated in vivo. Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental cell therapy that eliminates only one type of liver cell, the stellate cells that express fibroblast activation protein alpha (FAP). This strategy not only reduced fibrosis but also reversed liver damage.

Dispatch Bio’s DISP-10 gains IND clearance for solid tumors

Tue, 13 Jan 2026 08:00:00 -0500

Dispatch Biotherapeutics Inc. has obtained IND clearance from the FDA for DISP-10, enabling the initiation of a phase I study in patients with solid tumors. Initial clinical evaluation will begin in gastrointestinal cancers, with plans to expand into multiple additional solid tumor indications following clinical proof of concept.

Development and characterization of anti-CD19 in vivo CAR T therapy

Mon, 29 Dec 2025 08:00:00 -0500

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR T candidate, named GT-801.

IMV-101 shows promise for B-cell malignancies

Wed, 24 Dec 2025 08:00:00 -0500

IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and autoimmune diseases. The company has presented results of the evaluation of its in vitro and in vivo properties.

Further financing at Vyriad to advance VV-169 into clinic

Wed, 24 Dec 2025 08:00:00 -0500

Vyriad Inc. has announced the closing of a $25 million final tranche to its series B financing, bringing the total series B round to $85 million. This additional funding will support first-in-human testing of VV-169, Vyriad’s in vivo CAR T candidate, in patients with relapsed or treatment-refractory multiple myeloma.

AERA-109 successfully fights B-cell-mediated autoimmune disorders

Wed, 17 Dec 2025 08:00:00 -0500

Researchers from Aera Therapeutics Inc. reported the preclinical profile of AERA-109, a novel, targeted in vivo CAR T therapy designed to treat B-cell-mediated autoimmune diseases.

Allogeneic CAR-NKT cells potent against primary and metastatic pancreatic cancer

Mon, 15 Dec 2025 08:00:00 -0500

Pancreatic cancer is a leading cause of cancer-related deaths worldwide and presents a 5-year survival rate of under 12%. Most patients are diagnosed at an advanced stage, with over half of them presenting with metastatic disease at diagnosis.

Avencell’s AVC-203 cleared for clinic for B-cell malignancies

Fri, 05 Dec 2025 08:00:00 -0500

Avencell Therapeutics Inc. has received clinical trial clearances from the FDA and EMA to conduct a phase I/II trial (Quadvance) of AVC-203 for the treatment of relapsed or refractory B-cell malignancies.

Targeting tenascin-C enhances survival in glioblastoma studies

Wed, 03 Dec 2025 08:00:00 -0500

Glioblastomas (GBMs) are the most prevalent and highly lethal primary brain tumors and currently rely on limited treatment options. Chimeric antigen receptor (CAR) T cells targeting cell-surface antigens have shown promise in GBM patients, inducing transient tumor regression. However, the lack of known tumor-restricted antigens in GBM limits further improvement of their therapeutic efficacy.

CRAFT CAR T cells: Using CRISPR with reduced off-target risks

Mon, 01 Dec 2025 08:00:00 -0500

Allogeneic CAR T-cell therapy offers several advantages over an individualized autologous CAR T approach, thanks to the use of readily available, higher quality and quantity of starting donor T cells and the potential to generate multiple doses from a single manufacturing process.